Bard Peripheral Vascular, Inc. v. W.L. Gore & Associates, Inc.
In 1984 W.L. Gore & Associates (Gore) obtained an option from Bard Peripheral Vascular (Bard) to license any patent resulting from a patent application that issued in 2002 as the…
Biotechnology Manufacturing Agreement
A U.S. company that owned a patented biotechnology product engaged a European contractor to produce the product for commercial sale.
Biotechnology Monopolization Class Action
Counsel for a biotechnology firm retained Cornerstone Research in a class action monopolization case.
Biotechnology Shareholder Breach of Fiduciary Duty
Minority shareholders in a financially troubled biotechnology company alleged that the majority shareholder drove the company’s choices of funding sources and that the interests of minority shareholders were not properly…
Cancer Therapies
The owner of a patent for technology employed in the manufacture of a drug used in certain cancer therapies alleged that the pharmaceutical company that developed and manufactured the drug…
Commercial Success
In the liability phase of a pharmaceutical patent infringement lawsuit, the branded drug manufacturer may offer evidence of commercial success that flows from the patent to support a finding of…
Commercially Reasonable Efforts
Counsel for a biopharmaceutical company retained Cornerstone Research to address claims being arbitrated that it had breached a contractual obligation by failing to use diligent and commercially reasonable efforts to…
Cost Shifting
Cost shifting refers to the practice of increasing the price or markup charged to one group of patients in response to a decrease in another group’s price or markup.
Damages in Life-Cycle Management Case
Cornerstone Research assisted counsel in evaluating possible damages in a case where a branded pharmaceutical company was accused of delaying generic competition through various mechanisms.
Delayed Generic Competition
Counsel for a generic pharmaceutical company retained Cornerstone Research to assess the company’s incentives to launch a generic drug while ongoing patent litigation remained unresolved.
Delayed Generic Entry
Counsel for a branded pharmaceutical company retained Dr. Michael Keeley, a senior vice president of Cornerstone Research, to address class certification issues in two antitrust suits brought by classes of…
Direct Purchaser Antitrust Suit
Counsel for a leading U.S. manufacturer of medical devices retained Dr. Michael Keeley, a senior vice president of Cornerstone Research, to address class certification issues in an antitrust case brought…
How can we help you?
If you are looking for a publication not on our website, contact us.